Related Experiment Video

Updated: Feb 18, 2026

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing ChIP-seq
09:52

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing ChIP-seq

Published on: April 19, 2013

24.9K

ACAT-1 gene polymorphism is associated with increased susceptibility to coronary artery disease in Chinese Han

Yong-Tao Wang1,2, Ying-Hong Wang1,2, Yi-Tong Ma1,2

  • 1Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, P.R. China.

Oncotarget
|November 29, 2017
PubMed

Insights

Genetic variations in Acyl-CoA: cholesterol acyltransferase-1 (ACAT-1) influence coronary artery disease (CAD) risk. Specific ACAT-1 polymorphisms, rs11545566 and rs10913733, are linked to increased CAD risk and severity.

Area of Science:

  • Genetics
  • Cardiovascular Medicine
  • Biochemistry

Background:

  • Acyl-CoA: cholesterol acyltransferase-1 (ACAT-1) plays a role in atherosclerosis development.
  • Genetic factors may influence an individual's susceptibility to coronary artery disease (CAD).

Purpose of the Study:

  • To investigate the correlation between genetic variations in ACAT-1 genes and the risk of developing CAD.
  • To assess the association between ACAT-1 polymorphisms and the severity of CAD.

Main Methods:

  • Genotyping of four ACAT-1 polymorphisms (rs1044925, rs11545566, rs12121758, rs10913733) in 750 CAD patients and 580 healthy controls.
  • Utilized the improved multiplex ligation detection reaction (iMLDR) method for genotyping.
  • Employed multivariate linear regression analysis to correlate genotypes with Gensini scores.

Main Results:

  • The rs11545566 G allele was significantly associated with elevated CAD risk (AOR = 1.67, P = 0.001).
  • The rs10913733 G allele also showed a significant association with increased CAD risk (AOR = 1.39, P = 0.013).
  • The rs11545566 polymorphism was independently associated with Gensini scores, indicating a link to CAD severity (P = 0.005).

Conclusions:

  • ACAT-1 gene polymorphisms rs11545566 and rs10913733 are novel genetic factors contributing to CAD development.
  • The rs11545566 polymorphism is associated with the severity of coronary artery disease.

Keywords:
ACAT-1 geneassociation studiescoronary artery diseasepolymorphismsusceptibility

More Related Videos

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.3K
Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes11:33

Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes

Published on: March 12, 2013

13.8K

Related Concept Videos

Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
18.6K
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
15.8K
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.2K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
10
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
18
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
10